Immunis, Inc.

Overview

Immunis, Inc. is a clinical-stage biotechnology company based in Irvine, California, focused on developing multi-active biologics derived from stem cell secretomes. Founded in 2019, the company aims to address age-related diseases and immune system dysfunction through innovative secretome-based therapies. These therapies provide a natural, cell-free alternative to traditional stem cell treatments, minimizing risks such as immune rejection.

The lead product, IMM01-STEM, is designed to combat sarcopenia and immune dysregulation associated with aging. It contains bioactive molecules that have shown promise in improving muscle mass and strength in preclinical studies. The company has completed a Phase 1/2a clinical trial for IMM01-STEM and is currently conducting a Phase 2 study in adults with sarcopenic obesity. It targets elderly populations and patients experiencing immune dysregulation, positioning its therapies as alternatives to surgery for conditions like knee osteoarthritis.

Basic Information

Contact Details

• Phone: +1 949-466-0380
• Website: immunisbiomedical.com
• LinkedIn: linkedin.com/company/immunisbiomedical

Key Focus Areas & Initiatives

• sarcopenia
• metabolism
• muscle atrophy
• human healthspan
• cell therapy
• muscle health
• secretome
• obesity
• biotechnology research

Technologies Used

• AI
• Outlook
• Remote
• Render

Affiliated Organizations & Regional Branches